Hallucinogens for terminal cancer patients

In 2004, the scientific community turned its gaze towards Charles Grob of the Harbor-UCLA University, Los Angeles (USA). The U.S. Food and Drug, FDA, authorized his pioneering study of hallucinogenic drugs to terminally ill with cancer. The controversy not long in coming and now, surely, will make itself felt again.
For Grob has just published the results of that test, the first in 35 years that explores the usefulness of drugs like LSD or psilocybin, and the Hallucinogens for cancer patients, which is extracted from certain fungi, for anxiety and psychological stress associated with the existential crisis suffered Many terminally ill patients. And, apparently, their use also is effective insurance.
The American scientist expects no return "to play the bitter debate in the early 60s. I think we've matured enough as a culture for the past forty years to be able to refer to these compounds to a rigorous controlled study for Hallucinogens for cancer patients, scientific and accurately determine its range of effects, particularly the security settings and potential therapeutic applications, without political or social agents interfere with these tasks. "

Hallucinogens for cancer patients

In recent years, fortunately, health workers' awareness has grown that psychological and spiritual needs of many patients with cancer and their families should be approached with much more determination and the Hallucinogens for cancer patients. From the late 1950s to early 70s, were carried investigations aimed at exploring the use of hallucinogenic substances for the therapy of anxiety, despair and isolation often associated with advanced stages of cancer ...
The study showed that people in critical condition substantially improved and sustained their morale and their anxiety levels, and require fewer doses of narcotics and Hallucinogens for cancer patients for pain because of them. Despite these promising results, research into this field is stopped, "says Dr. Grob in the past ' Archives of General Psychiatry.